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Abstract
OBJECTIVE: Benzodiazepines and anticholinergics are risk factors for delirium in the intensive 
care unit (ICU). We tested the impact of a deprescribing intervention on short-term delirium 
outcomes.
DESIGN: Multi-site randomized clinical trial
SETTING: ICU’s of three large hospitals
PARTICIPANTS: Two hundred adults aged ≥ 18 years admitted to an ICU with delirium 
according to the Richmond Agitation Severity Scale and the Confusion Assessment Method for 
the ICU (CAM-ICU). Participants had a contraindication to haloperidol (seizure disorder or 
prolonged QT interval) or preference against haloperidol as a treatment for delirium, and were 
excluded for serious mental illness, stroke, pregnancy or alcohol withdrawal. Participants were 
randomized to a deprescribing intervention or usual care. The intervention included electronic 
alerts combined with pharmacist support to deprescribe anticholinergics and benzodiazepines.
MEASUREMENTS: Primary outcomes were delirium duration measured by the CAM-ICU, and 
severity measured by the Delirium Rating Scale Revised-98 (DRS-R-98) and the CAM-ICU-7; 
secondary outcomes included adverse events and mortality.
RESULTS: Participants had a mean age of 61.8 (standard deviation: 14.3) years, 59% female, and 
52% African American with no significant differences in baseline characteristics between groups. 
No differences between groups were identified in the number exposed to anticholinergics 
(p=0.219) or benzodiazepines (p=0.566), the median total anticholinergic score (p=0.282), or the 
median total benzodiazepine dose in lorazepam equivalents (p=0.501). Neither median delirium/
coma-free days (p=0.361) nor median change in delirium severity scores (p=0.582 for DRS-R-98; 
p=0.333 for CAM-ICU-7) were different between groups. No differences in adverse events or 
mortality were identified.
CONCLUSIONS: When added to state-of-the-art clinical services, this deprescribing 
intervention had no impact on medication use in ICU participants. Given the age of the population, 
results of clinical outcomes may not be easily extrapolated to older adults. Nonetheless, improved 
approaches for deprescribing or preventing anticholinergics and benzodiazepines should be 
developed to determine the impact on delirium outcomes.
Keywords
delirium; deprescribing; anticholinergic; benzodiazepine
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Introduction
Deprescribing interventions are hypothesized to reduce the future risk of drug-induced 
adverse events.1,2 We previously tested the impact of a deprescribing intervention in an 
electronic medical record (EMR) system to reduce exposure to anticholinergics among older 
adults with delirium or dementia in a general medical ward.3 In hospitalized patients, 
anticholinergics and benzodiazepines worsen neurotransmitter imbalances of cholinergic 
deficiency, and dopaminergic and gamma-aminobutyric acid (GABA) excess leading to 
higher risk of delirium.4–8 While our initial EMR-based deprescribing intervention did not 
reduce new orders for anticholinergics, it modestly increased discontinuation orders; 
however, no impact on clinical outcomes was identified.3
Feedback from providers exposed to the EMR-based intervention suggested the intervention 
failed to change prescribing habits due to a non-interruptive nature of the alert, and lack of 
human decision support.3 Based on this feedback, we enhanced the electronic deprescribing 
intervention by designing an interruptive alert that offered recommendations for alternative 
(non-anticholinergic) medications with easy-to-order keystrokes, and a pharmacist 
supporting the intervention through direct clinical support to medical and surgical teams.9
Delirium in critically ill adults has been associated with longer hospital stays and higher 
mortality, and higher rates of long-term cognitive impairment.10–18 Because no medication 
is FDA-approved for the treatment of delirium, we developed a multi-component approach 
to delirium treatment in the intensive care unit (ICU) based on the neurotransmitter models 
described above, called the pharmacological management of delirium (PMD).8,9,19 PMD 
includes deprescribing anticholinergics and benzodiazepines, and prescribing low dose 
haloperidol for 7 days. However, some patients in the ICU possess contraindications to 
haloperidol, such as prolonged QT intervals or seizure disorder, or have personal preference 
against using haloperidol for an off-label indication. Therefore, we performed two parallel, 
pragmatic randomized trials of the PMD intervention, one that employed all three 
components of the intervention (PMD),19 and this trial that employed only the deprescribing 
interventions (de-PMD). Our hypothesis for both trials was that participants receiving the 
intervention would have (1) higher number of days without delirium or coma, and (2) lower 
delirium severity.
Methods:
The Institutional Review Board of Indiana University (IU) Purdue University Indianapolis 
approved the study. Participants’ legally authorized representatives provided informed 
consent prior to enrollment.9
Study Setting:
The study was conducted within the ICU’s of Eskenazi Health, Indiana University (IU) 
Methodist Hospital, and IU University Hospital. Eskenazi hospital hosts three intensive care 
units: an 8-bed surgical ICU (SICU), a 14-bed medical ICU (MICU) and a 29-bed 
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progressive ICU (PICU, a step-down unit). IU Methodist Hospital includes 65 mixed MICU 
and SICU beds, and IU Health University hospital included 36 MICU and SICU beds.
Enrollment, Eligibility and Randomization (See figure 1):
Inclusion criteria consisted of the following: (1) patients admitted to the ICU ward for ≥ 24 
hours, (2) age ≥ 18 years, (3) screen positive for delirium based on the Richmond Agitation-
Sedation Scale (RASS)20 and the Confusion Assessment Method for the ICU (CAM-
ICU)21,22 on any day during the ICU stay, (4) had a contraindication to haloperidol (such as 
QT prolongation or seizure disorder) or personal preference to avoid exposure to haloperidol 
as a delirium treatment, and (5) are English-speaking. Patients were excluded if they had 1) 
history of severe mental illness, 2) delirium due to alcohol intoxication, 3) aphasic stroke, 4) 
were pregnant or nursing, or 5) previously been enrolled in the study. Randomization of 
eligible patients occurred in a 1:1 ratio between the intervention and usual care groups 
utilizing computer-generated allocation in random blocks of four.
Intervention content and delivery:
The intervention consisted of a multi-component decision aid preventing or deprescribing 
definite anticholinergic medications and benzodiazepines (including the benzodiazepine-
receptor agonist zolpidem).9 Briefly, two methods were employed: 1) a computerized 
decision support intervention to interrupt orders for strong anticholinergics, and 2) human 
(pharmacist) decision support that included twice-daily surveillance of medication orders 
and administration records. After randomization to the intervention, computerized alerts 
were triggered with new or renewal orders for definite anticholinergics identified according 
to the Anticholinergic Cognitive Burden (ACB) scale and included in the hospital 
formularies (see supplemental material for screenshots of computerized alerts and 
alternatives).7,23–26 Alerts were interruptive, provided brief education of the risk of 
anticholinergics, and recommended a non-anticholinergic alternative. The human decision 
support (intervention pharmacist performing twice daily medication reviews) identified 
anticholinergics prescribed despite the computerized alerts and communicated directly with 
the primary medical and surgical ICU teams to offer alternatives.9 The intervention intended 
to align prescribing practices with state-of-the-art care for anticholinergics and 
benzodiazepines in the ICU.27–29
Usual Care:
Those randomized to the usual care group received no electronic or human decision support 
for pharmacologic management of delirium throughout their hospital stay. Low dose 
haloperidol was not included as part of this intervention, however providers could prescribe 
haloperidol without restriction on dose, frequency, or duration to those enrolled in either 
group.
At all study sites, and over the course of the trial, implementation of new standards of care 
were introduced at each study site.27 These care bundles include the ABCDE bundle 
(Awakening and Breathing Coordination, Delirium monitoring and management, and Early 
mobility). These practices have been shown in prior studies to reduce the duration of 
mechanical ventilation, length of ICU stay, and mortality.30–33
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Primary Outcomes:
a) Delirium Duration.—We identified delirium using the Richmond Agitation Sedation 
Scale (RASS)20 and the Confusion Assessment Method for the ICU (CAM-ICU).21,22 The 
CAM-ICU was chosen based on the recommendation of national guidelines,27 its practical 
use in the ICU and its acceptable psychometric properties.22 The CAM-ICU score was 
determined by examining (a) acute or fluctuating changes in mental status, (b) inattention, 
(c) altered level of consciousness, and (d) disorganized or incoherent thinking. CAM-ICU 
was considered to be positive if the patient displayed both (a) and (b), plus (c) and/or (d). 
RASS was utilized as a sister instrument to measure level of arousal alongside the CAM-
ICU.20 Patients with a RASS score of −3 to +4 were eligible for delirium assessment, while 
scores of −4 and −5 were characterized as comatose and not eligible for CAM-ICU 
assessment. Blinded research assistants conducted twice daily RASS and CAM-ICU 
assessments after 24 hours of ICU admission and until discharge from the hospital, death, or 
30 days after enrollment.
b) Delirium Severity: Delirium severity was assessed using the Delirium Rating Scale-
revised (DRS-R-98)34,35 and the CAM-ICU-7.36 The DRS-R-98 is a 16-item clinician-rated 
scale (rated 0 to 3, maximum 39 points) with higher scores indicating greater severity of 
delirium. The CAM-ICU-7 is a seven point rating scale (0–7, higher scores more severe) that 
has been derived from the RASS and the CAM-ICU. Severity assessments were performed 
by trained and blinded research assistants in a similar frequency reported above.
Secondary & Other Outcomes:
Secondary outcomes were collected through direct observation and the EMR, and included 
mortality rates (up to 30 days after discharge), length of stay (both ICU and total hospital 
stay) falls, use of physical restraints, pulling out intravenous lines or urinary catheters, re-
intubation, and pressure ulcers.13,37
We collected baseline demographic and clinical information from the EMR as well as each 
participant’s legally authorized representative. Prior cognitive function was obtained by 
legally authorized representatives using the Informant Questionnaire on Cognitive Decline in 
the Elderly (IQCODE).38,39 Activities of daily living and instrumental activities of daily 
living prior to ICU admission were assessed through Katz40 and Lawton41 scales, completed 
with input from participant’s legally authorized representatives. Electronic medical records 
were used to collect reasons for admission, severity of illness (APACHE II)42 within 24 
hours of admission to the ICU, daily mechanical ventilation status, and the Charlson 
Comobidity Index.43 Medication data included drug, dose, time administered, and route was 
collected manually from hospital administration records. Cumulative or total use by 
medication or class is reported as a sum of each dose administered.
Sample Size:
Since this trial was conducted in ICU patients with contraindications to haloperidol, we did 
not set a sample size a priori. Instead, enrollment to the trial occurred concurrently with the 
PMD trial19 and was stopped at the end of funding support. Using the two-sample t-test for 
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continuous outcomes, we estimate that the sample size of 100 in each group provides 80% 
power for detecting a group difference with effect size of 0.4 SD or greater.
Drug-related adverse events:
Adverse effects were monitored using EMRs and direct observation throughout the hospital 
stay or up to 30 days after enrollment. Likelihood for causality with study interventions was 
assessed using the Naranjo scale.44 All adverse events were reported to an independent Data 
Safety Monitoring Board (DSMB).
Data Analyses:
Baseline differences between groups were assessed using Fisher’s exact tests for categorical 
outcomes and Wilcoxon-Rank sum tests for continuous measures with skewed data. 
Additionally, we used Fisher’s exact test to compare the percentage of patients who received 
targeted medications, complications, and adverse events. To test for differences in the 
number of adverse events and total and daily medication doses between groups, we used the 
Wilcoxon-Rank sum test.
Delirium/coma free days and length of stay were compared using the nonparametric 
Wilcoxon Rank-Sum test. Two time points were used for delirium/coma free days and for 
delirium severity: day 8 post-randomization as this was the end of the haloperidol course in 
the intervention group, and at discharge. Patients who died before day 8 or discharge had 
their subsequent delirium/coma free days counted as 0. Patients who were discharged before 
day 8 had the remaining days counted as delirium/coma free. To adjust for length of stay 
when comparing delirium/coma free days at discharge, we used a Poisson regression model 
that included an offset equal to the log of length of stay post randomization.
Since delirium severity measured by DRS-R-98 had substantial missing values, we used 
multiple imputation methods to compare change in DRS-R-98 scores from baseline to day 8 
or discharge. We used both regression and propensity-based methods for multiple 
imputation. The MI procedure in SAS was used to create a set of 30 imputed datasets using 
the following variables: day post randomization, morning/afternoon assessment, mechanical 
ventilation, RASS score, coma, delirium, and 4 variables obtained from chart review 
(hallucinations, delusions, confusion, and disorientation). We used the MIANALYZE 
procedure in SAS to compare DRS-R-98 scores at baseline, day 8, discharge, and change 
scores between the two groups. Results were similar for both imputation procedures, 
therefore, we report the regression-based imputation. A mixed effects model with mean 
daily CAM-ICU-7 scores as the dependent variable was used to compare the difference in 
CAM-ICU-7 change from baseline to day 8 or to discharge. The mixed model included 
randomization group, time, group and time interaction as independent variables and a 
random effect for patients.
We used Fisher’s exact tests to examine differences in mortality at ICU and hospital 
discharge, and 30 days post discharge. The Wilcoxon-Rank sum test was used to compare 
length of stay, ICU length of stay, and days on mechanical ventilation post randomization.
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All analyses were calculated on an intention-to-treat basis. The analyses were conducted in 
all patients (including those who withdrew) using available data until time of death, 
discharge, withdrawal or 30 days after enrollment. Analyses were conducted using SAS 
v9.4.
Results:
Participants:
The supplemental file (Supplemental Figure) contains the CONSORT diagram shows the 
flow of participants through screening and study completion. The study screened 12,402 
ICU patients for eligibility, with 6,653 never experiencing delirium (53.6%), and 4,183 
(33.7%) meeting other exclusion criteria and not eligible for this trial. As described above, 
this trial occurred in parallel with the PMD delirium treatment trial that included low-dose 
haloperidol in addition to deprescribing benzodiazepines and anticholinergics; eight 
participants with prolonged QT intervals were screened for the parallel trail (PMD) but 
before this trial was initiated and were therefore excluded. Among those eligible, 351 were 
enrolled in the PMD trial and 200 in this de-PMD trial. Supplemental table 3 reports the 
distribution of contraindications to haloperidol and the proportions who received haloperidol 
through routine clinical care.
Participant Characteristics:
As seen in table 1, the mean age of participants was 61.8 (standard deviation (SD) 14.3 
years), 59% were female and 52% were African American. Study groups did not differ 
significantly with respect to age, gender, race, education, comorbidities, acute severity of 
illness, and discharge diagnosis. The majority of participants were admitted to the medical 
ICU services (74%) and received mechanical ventilation for at least one day (72%). Almost 
half were admitted with acute respiratory failure and/or sepsis (49%), while 24% were 
admitted for altered mental status or other neurological diagnoses.
Primary Outcomes:
No difference in the median number of days without delirium or coma was identified 
between those randomized to the intervention compared to usual care groups at either day 8 
[p=0.361] or 30 days after randomization [p=0.108] (Figure and Supplemental Table 2). 
Similarly, no difference in the mean reduction in delirium severity scores was seen between 
groups as measured by either the DRS-R98 or CAM-ICU-7 from baseline to day 8 or 
discharge (Figure and Supplemental Table 2).
Secondary Outcomes:
No differences in secondary outcomes, including ICU mortality [p=0.794], in-hospital 
mortality [p=0.478], 30-day mortality [p=0.291], number of days ventilated [p=0.242], 
number of hospital days post-randomization [p=0.246], and number discharged to home 
[p=0.447] were identified between groups (Supplemental Table 2). Those randomized to 
intervention had a higher median number of ICU days after randomization [p=0.019].
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Measures of Medication Use:
Table 2 and Supplemental Table 1 describe characteristics of exposure to analgosedatives 
used in the study population, with benzodiazepines and anticholinergics reported as 
lorazepam equivalents and anticholinergic burden scores, respectively. Target medication 
exposure is reported by group and time (defined as prior to enrollment, day-of 
randomization, and post-randomization periods). The deprescribing intervention did not 
change the number exposed or median total dose of lorazepam equivalents between groups 
[intervention: 38.3 mg (IQR 98.6mg) vs. usual care: 37.7 (IQR 115.9mg); p=0.501]. 
Although the intervention group had a lower mean total ACB score (a cumulative measure 
of exposure), the difference was not statistically significant [intervention: 4.3 (SD 8.8) vs. 
usual care: 6.1 (SD 16.6); p=0.282]. The median number of days an anticholinergic was 
administered among those receiving any anticholinergic was lower but not significantly 
different between groups [intervention: 3.5 (IQR 1–7) vs. usual care: 4 (IQR 1–15); p=0.32]. 
To better identify potential subgroups in which the de-PMD intervention reduced 
anticholinergic use, we explored differences between study group and age, service, and time 
since enrollment, though we note the study was not powered to detect differences in 
subgroups. Participants in SICU service teams showed differences approaching statistical 
significance; the median (IQR) number of anticholinergic doses among SICU participants in 
the intervention group receiving at least one dose of anticholinergics was 5 (2–8.5) 
compared to 6 (1–19) in usual care [p=0.114]. The median (IQR) number of doses among 
those age 65 and over and receiving at least one anticholinergic dose was 4.5 (1–12) in the 
intervention group and 8 (2–15) [p=0.604] in the usual care group.
Adverse Events:
Twenty-seven participants in the intervention group and twenty-two in the usual care group 
experienced a serious adverse event (p=0.413). Table 3 describes the distribution of all 
adverse events recorded by study assessors with no differences between groups observed. 
Intervention participants experienced a higher rate of pulling out respiratory, gastrointestinal, 
or intravenous access hardware compared to usual care [p=0.033]. Supplemental Table 4 
reports no differences in the distribution of delirium psychomotor subtypes by study group 
based on RASS scores.
Discussion:
This randomized trial showed that our electronic and pharmacist-based deprescribing 
intervention had no significant impact on the number exposed, median or total dose of 
anticholinergics and benzodiazepines, and therefore did not change delirium, length of stay, 
or mortality outcomes among critically ill adults with delirium. Despite 58% of participants 
being exposed to at least one dose of benzodiazepines in the post-randomization period, and 
30% of participants exposed to strong anticholinergics, the mean and median daily dose of 
benzodiazepines and anticholinergics was low (table 3). Our combined deprescribing 
intervention failed to further reduce measures of medication use and therefore could not 
determine whether deprescribing these medications can reduce delirium outcomes.
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The failure of our intervention to influence anticholinergic and benzodiazepine exposure 
could be attributed to a number of factors related to the design of the intervention as well as 
the clinical environment in which the study was conducted. First, our intervention employed 
an interruptive alert and recommendation of alternatives within the EMR at the time of order 
entry. Our prior experience with approaches in preventing anticholinergic orders also failed 
to reduce exposure to anticholinergics.3 Although we included a pharmacist review of 
medications, our alert was not triggered for pre-existing orders, which may have inflated the 
number of participants ever exposed to a target medication. Additionally, the intervention 
did not intend to change sedation practices, which frequently employed benzodiazepines 
among ventilated participants. During the study, an updated clinical practice guideline for 
the management of pain, agitation, and delirium in critically ill adults recommended the 
minimization of benzodiazepines and anticholinergics.27 This may have resulted in 
contamination, compromising our ability to influence medication use. We note that medical 
and surgical ICU teams in each study site received support from clinical pharmacists who 
have post-graduate training in critical care, participate in rounds with ICU teams on a daily 
basis, have an influence in sedation and pain management practices, and have access to all 
clinical data relevant to the care of delirium and other medical illnesses. Therefore our 
results may be different in healthcare systems without comprehensive clinical pharmacy 
support.
While we believe the use of electronic medical records offer a scalable opportunity for 
deprescribing interventions, our experience in this and prior trials suggest that our approach 
should not be repeated.3,19 Future deprescribing trials should be improved with attention to 
the design and timing of alerts as well as the incorporation of behavior change theories 
including priming and default settings,45 A successful EMR-based deprescribing 
intervention could have scalable opportunities not only in acute care environments, but also 
primary care and rehabilitation or extended care facilities. We note, however, that given the 
age of the population studied, results of clinical outcomes may not be easily extrapolated to 
older adults.
Our study had limitations worth noting: 1) this study was conducted in three urban academic 
hospitals with a diverse population, and consistent clinical pharmacy support and may not be 
generalizable to other institutions; 2) participants who were not users of benzodiazepine or 
anticholinergics did not receive any intervention which reduced our ability to measure 
impact; 3) our design called for randomization of the participant rather than provider or site, 
therefore contamination among both providers and clinical pharmacists may have 
compromised the impact of our intervention and results; and 4) the computerized 
intervention was not triggered for existing medication orders and may have been more 
effective in the prevention of medication use and ultimately delirium prevention.
Conclusion
This multi-component deprescribing intervention did not significantly reduce 
benzodiazepine or anticholinergic use compared to usual care among adults admitted to the 
ICU, and therefore could not influence delirium outcomes. Improving the efficacy of 
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deprescribing interventions with more attention to the decision processes of deprescribing 
could improve future research in reducing delirium outcomes in ICU populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Primary Outcomes of de-PMD: Coma/Delirium Free Days (a) and Change in Delirium 
Severity Scores (b).
Reporting of primary outcomes of median (interquartile range) number of days alive without 
delirium or coma at day 8 and day 30 (a), and the mean (standard deviation) reduction from 
baseline in delirium severity scores at day 8 and discharge according to the Delirium Rating 
Scale-Revised-1998 and the Confusion Assessment Method for the Intensive Care Unit-7 
(b).
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Table 1:
Baseline Characteristics of enrolled participants (n=200)
Overall de-PMD
(N=99)
Usual Care
(N=101)
Age 61.8 (14.3) 61.3 (14.6) 62.4 (14.1)
Female n (%) 118 (59.0) 65 (65.7) 53 (52.5)
African-American n (%) 102 (52.0) 54 (55.1) 48 (49.0)
Education (years) 11.6 (2.1) 11.5 (2.1) 11.6 (2.1)
APACHEa II 21.2 (8.3) 20.6 (8.2) 21.7 (8.3)
Charlson Comorbidity Index 3.2 (2.5) 3.2 (2.5) 3.2 (2.4)
Activities of Daily Living (ADL)b 5.3 (1.4) 5.3 (1.4) 5.3 (1.5)
Instrumental Activities of Daily Living (IADL)c 5.6 (2.8) 5.5 (2.8) 5.7 (1.5)
IQCODEd 3.3 (0.5) 3.3 (0.4) 3.3 (0.5)
Mechanically Ventilated n (%) 143 (71.9) 73 (73.7) 70 (70.0)
ICU Location
Medical ICUe n (%) 147 (73.9) 72 (72.7) 75 (75.0)
Surgical ICU n (%) 35 (17.6) 20 (20.2) 15 (15.0)
Progressive/step-down ICU n (%) 17 (8.5) 7 (7.1) 10 (10.0)
Diagnoses
Acute Respiratory Failure/Sepsis 98 (49.0) 50 (50.5) 47 (47.5)
Neurologic/Altered Mental Status 47 (23.5) 23 (23.2) 24 (23.8)
Trauma 16 (8.0) 6 (6.1) 10 (9.9)
Otherf 39 (19.5) 20 (20.2) 19 (18.8)
Data presented as mean (standard deviation) unless otherwise specified
aAPACHE: Acute Physiology and Chronic Health evaluation
bADLs assessed by Katz Scale
c
IADLs assessed by Lawton Scale
d
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly
e
ICU: Intensive Care Unit
fOthers: Include cardiovascular and gastrointestinal diagnoses
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Table 2:
de-PMD Trial Medication Exposures
Pre-Randomization Randomization Day Post-Randomization
de-PMD*
(N=99)
Usual
Care
(N=100)
P-
value
de-PMD
(N=99)
Usual
Care
(N=100)
P-
value
de-PMD
(N=99)
Usual
Care
(N=100)
P-
value
Haloperidol
 Patients† n (%) 7 (7.1) 13 (13.0) 0.238 6.1 (6) 8.0 (8) 0.783 29 (29.3) 20 (20.0) 0.141
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.176 0 (0–0) 0 (0–0) 0.575 0 (0–0.2) 0 (0–0) 0.117
Benzodiazepines‡
 Patients† n (%) 69 (69.7) 58 (58.0) 0.105 37 (37.4) 35.0 (35) 0.769 60 (60.6) 56 (56.0) 0.566
 Median daily Dose 
(IQR)
1.1 (0–10.0) 0.3 (0–3.7) 0.044 0 (0–4) 0 (0–2) 0.550 0.1 (0–1.2) 0.1 (0–1.1) 0.634
Anticholinergic Burden§
 Patients† n (%) 16 (16.2) 15 (15.0) 0.847 11 (11.1) 12 (12.0) 1.000 34 (34.3) 26 (26.0) 0.219
 Median daily score 
(IQR)
0 (0–0) 0 (0–0) 0.832 0 (0–0) 0 (0–0) 0.823 0 (0–0.3) 0 (0–0.1) 0.266
Olanzapine
 Patients† n (%) 3 (3.0) 1 (1.0) 0.369 3 (3.0) 1 (1.0) 0.369 4 (4.0) 2 (2.0) 0.445
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.306 0 (0–0) 0 (0–0) 0.306 0 (0–0) 0 (0–0) 0.387
Quetiapine
 Patient† s n (%) 4 (4.0) 6 (6.0) 0.748 3 (3.0) 5 (5.0) 0.721 8 (8.1) 9 (9.0) 1.000
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.509 0 (0–0) 0 (0–0) 0.461 0 (0–0) 0 (0–0) 0.776
Risperidone
 Patients† n (%) 0 (0.0) 1 (1.0) 1.000 0 (0.0) 0 (0.0) 1 (1.0) 1 (1.0) 1.000
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.320 0 (0–0) 0 (0–0) 1.000 0 (0–0) 0 (0–0) 0.989
Dexmedetomidine
 Patients† n (%) 10 (10.1) 5 (5.0) 0.191 2 (2.0) 2 (2.0) 1.000 6 (6.1) 11 (110) 0.311
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.175 0 (0–0) 0 (0–0) 0.992 0 (0–0) 0 (0–0) 0.218
Opioids ∥
 Patients† n (%) 86 (86.9) 76 (76.0) 0.068 68 (68.7) 62 (62.0) 0.372 83 (83.8) 70 (70.0) 0.028
 Median daily Dose 
(IQR)
35.9 (2.5–77.8) 27.5 (0.6–87.2) 0.522 36.8 (0–107.5) 24.1 (0–88.4) 0.460 6.3 (0.8–44.1) 3.5 (0–34.6) 0.078
Propofol
 Patients† n (%) 41 (41.4) 45 (45.0) 0.668 22 (22.2) 28 (28.0) 0.414 38 (38.4) 27 (27.0) 0.098
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Pre-Randomization Randomization Day Post-Randomization
de-PMD*
(N=99)
Usual
Care
(N=100)
P-
value
de-PMD
(N=99)
Usual
Care
(N=100)
P-
value
de-PMD
(N=99)
Usual
Care
(N=100)
P-
value
 Median daily Dose 
(IQR)
0 (0–144) 0 (0–906) 0.304 0 (0–0) 0 (0–229) 0.508 0 (0–199) 0 (0–1) 0.088
Clonidine
 Patients† n (%) 2 (2.0) 3 (3.0) 1.000 1 (1.0) 3 (3.0) 0.621 6 (6.1) 7 (7.0) 1.000
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.653 0 (0–0) 0 (0–0) 0.321 0 (0–0) 0 (0–0) 0.780
Propranolol
 Patients† n (%) 2 (2.0) 0 (0.0) 0.246 0 (0.0) 0 (0.0) 3 (3.0) 3 (3.0) 1.000
 Median daily Dose 
(IQR)
0 (0–0) 0 (0–0) 0.154 0 (0–0) 0 (0–0) 1.000 0 (0–0) 0 (0–0) 0.974
*de-PMD: deprescribing in the Pharmacological Management of Delirium
†
Patients who received the drug during hospitalization
‡
Benzodiazepine data presented as Lorazepam equivalents and includes zolpidem
§Anticholinergic burden measured by Anticholinergic Burden (ACB) scale
∥Opioids data presented as morphine equivalents
Haloperidol dose is presented in milligrams (mg)
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Table 3.
Comparison of Adverse Events between de-PMD and Usual Care Groups
de-PMD
(n=99)
Usual Care
(n=101)
P-value
Patients with Serious Adverse Event 27 (27.3) 22 (21.8) 0.413
Total Number of Serious Adverse Events 37 35
Event Type*
Death 11 (11.1) 8 (7.9) 0.478
QT prolongation 0 (0) 0 (0) N/A
Cardiac Arrhythmias 1 (1.0) 1 (1.0) 1.000
Extra Pyramidal Symptoms 0 (0) 0 (0) N/A
Neuroleptic Malignant Syndrome 0 (0) 0 (0.0) N/A
Prolonged Hospitalization 5 (5.0) 2 (2.0) 0.277
Other 15 (15.2) 14 (13.9) 0.843
Relationship to Protocol
Event Definitely related 0 (0) 0 (0) N/A
Event Probably related 0 (0) 0 (0) N/A
Event Possibly related 0 (0) 0 (0) N/A
Organ System
Central Nervous System 4 (4.0) 2 (2.0) 0.443
Cardiovascular 10 (10.1) 9 (8.9) 0.814
Respiratory 11 (11.1) 12 (11.9) 1.000
Gastrointestinal 3 (3.0) 3 (3.0) 1.000
Genitourinary 0 (0.0) 4 (4.0) 0.121
Skin 1 (1.0) 0 (0.0) 0.495
Hepatic 0 (0) 0 (0) N/A
Hematologic 3 (3.0) 3 (3.0) 1.000
Endocrine 0 (0) 0 (0) N/A
Musculoskeletal 1 (1.0) 1 (1.0) 1.000
Delirium-related complications
Inappropriate attempt to get out of bed, N (%) 8 (8.1) 5 (5.0) 0.407
Verbal agitation, N (%) 5 (5.0) 5 (5.0) 1.000
Fall, N (%) 2 (2.0) 0 (0.0) 0.246
Delayed Procedure, N (%) 0 (0.0) 0 (0.0)
Pulling Tubes, N (%) 9 (9.1) 2 (2.0) 0.033
Hospital Acquired Pressure Ulcers, N (%) 18 (18.2) 10 (10.0) 0.107
Data presented as N (%) unless otherwise specified
*
Event types are presented as number of patients with the event. A single patient may have more than one adverse event
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